NCT02533453View on ClinicalTrials.gov

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 28, 2016

Primary Completion Date

December 7, 2016

Study Completion Date

December 7, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
BIOLOGICAL

Bydureon

exenatide once weekly

Trial Locations (15)

13620

Research Site, Seongnam-si

16499

Research Site, Suwon

26426

Research Site, Wŏnju

35015

Research Site, Daejeon

49241

Research Site, Busan

61469

Research Site, Gwangju

700-712

Research Site, Daegu

405-760

Research Site, Incheon

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

08308

Research Site, Seoul

130-872

Research Site, Seoul

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY